424 related articles for article (PubMed ID: 38077389)
21. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
22. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
[TBL] [Abstract][Full Text] [Related]
23. Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.
Sanchez-Martinez D; Allende-Vega N; Orecchioni S; Talarico G; Cornillon A; Vo DN; Rene C; Lu ZY; Krzywinska E; Anel A; Galvez EM; Pardo J; Robert B; Martineau P; Hicheri Y; Bertolini F; Cartron G; Villalba M
Theranostics; 2018; 8(14):3856-3869. PubMed ID: 30083264
[TBL] [Abstract][Full Text] [Related]
24. iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting.
Snyder KM; Dixon KJ; Davis Z; Hosking M; Hart G; Khaw M; Matson A; Bjordahl R; Hancock B; Shirinbak S; Miller JS; Valamehr B; Wu J; Walcheck B
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38056893
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.
Beelen NA; Ehlers FAI; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Apr; 72(4):797-804. PubMed ID: 36261539
[TBL] [Abstract][Full Text] [Related]
26. The Impact of NK Cell-Based Therapeutics for the Treatment of Lung Cancer for Biologics: Targets and Therapy.
Hamilton G; Plangger A
Biologics; 2021; 15():265-277. PubMed ID: 34262255
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
28. Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy.
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren HG; Nahi H; Wagner AK; Alici E
Cancer Immunol Immunother; 2023 May; 72(5):1153-1167. PubMed ID: 36355079
[TBL] [Abstract][Full Text] [Related]
29. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
30. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
[TBL] [Abstract][Full Text] [Related]
31. Weaponizing natural killer cells for solid cancer immunotherapy.
Wong JKM; Dolcetti R; Rhee H; Simpson F; Souza-Fonseca-Guimaraes F
Trends Cancer; 2023 Feb; 9(2):111-121. PubMed ID: 36379852
[TBL] [Abstract][Full Text] [Related]
32. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
33. Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells.
Gauthier M; Laroye C; Bensoussan D; Boura C; Decot V
Crit Rev Oncol Hematol; 2021 Apr; 160():103261. PubMed ID: 33607229
[TBL] [Abstract][Full Text] [Related]
34. Combination immune therapies to enhance anti-tumor responses by NK cells.
Mentlik James A; Cohen AD; Campbell KS
Front Immunol; 2013 Dec; 4():481. PubMed ID: 24391651
[TBL] [Abstract][Full Text] [Related]
35. Improving Immunotherapy Against B-Cell Malignancies Using γδ T-Cell-specific Stimulation and Therapeutic Monoclonal Antibodies.
Hoeres T; Pretscher D; Holzmann E; Smetak M; Birkmann J; Triebel J; Bertsch T; Wilhelm M
J Immunother; 2019; 42(9):331-344. PubMed ID: 31318724
[TBL] [Abstract][Full Text] [Related]
36. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
37. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
38. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
39. Antibody Afucosylation Augments CD16-Mediated Serial Killing and IFNγ Secretion by Human Natural Killer Cells.
Karampatzakis A; Brož P; Rey C; Önfelt B; Cruz De Matos GDS; Rycroft D; Ambrose A; Davis DM
Front Immunol; 2021; 12():641521. PubMed ID: 33796107
[TBL] [Abstract][Full Text] [Related]
40. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
